Table 3. Alterations detected in Colon cancer (CC) patients (n=31).
| Patient | SNV | Allele Frequency |
Validation (Sequencing) | CNA | Validation (RT-PCR) | Fusion |
|---|---|---|---|---|---|---|
| CC1 | BRAF-V600E | 32% | Sanger | |||
| CC2 | MTOR-T1977K KRAS-G12D |
7,5% 16% |
||||
| CC3 | ||||||
| CC4 | KRAS-A146T | 8% | FGFR1 (5) | Yes | ||
| CC5 | KRAS-G12C | 14% | ||||
| CC6 | PIK3CA-E542K KRAS-G12V |
30% 49% |
Sanger Sanger |
|||
| CC7 | PIK3CA-H1047R BRAF-V600E |
23% 22.5% |
Sanger | |||
| CC8 | PIK3CA-G1049C BRAF-V600E |
20% 19% |
Sanger Sanger |
|||
| CC9 | ||||||
| CC10 | ||||||
| CC11 | KRAS-A146T | 44.5% | ||||
| CC12 | NRAS-G61K | 25% | ||||
| CC13 | NGS Panel** | |||||
| CC14 | ||||||
| CC15 | ||||||
| CC16 | PIK3CA-H1047Y BRAF-V600E |
16.5% 9% |
||||
| CC17 | KRAS-G12S PIK3CA-E542K |
37.5% 39% |
||||
| CC18 | KRAS-G12V | 37.5% | ||||
| CC19 | KRAS-A146T | 57% | ||||
| CC20 | ||||||
| CC21 | NGS Panel | |||||
| CC22 | ||||||
| CC23 | ||||||
| CC24 | KRAS-G12V PIK3CA-E545K |
31% 39% |
||||
| CC25 | KRAS-G13D | 15% | ||||
| CC26 | KRAS-G12A ERBB3-G332K |
15% 5.5% |
||||
| CC27 | ||||||
| CC28 | KRAS-G12S EGFR-G719D NRAS-G61K |
33% 10% 38% |
Sanger | |||
| CC29 | KRAS-G13D PIK3CA-E545K |
31% 36% |
||||
| CC30 | RET-A883V KRAS-G12D AKT1-E17K |
9% 37% 11% |
||||
| CC31 | KRAS-G13D KRAS-A146T |
10% 38% |
** The NGS Panel used is the Comprehensive Cancer Panel from Thermofisher.